Your browser doesn't support javascript.
loading
Chimeric virus-like particles of human norovirus constructed by structure-guided epitope grafting elicit cross-reactive immunity against both GI.1 and GII.4 genotypes.
Hou, Ya Nan; Jin, Yu Qin; Zhang, Xue Feng; Tang, Fang; Hou, Jun Wei; Liu, Zhao Ming; Han, Zi Bo; Zhang, Hao; Du, Li Fang; Shao, Shuai; Su, Ji Guo; Liang, Yu; Zhang, Jing; Li, Qi Ming.
Afiliação
  • Hou YN; The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
  • Jin YQ; National Engineering Center for New Vaccine Research , Beijing, China.
  • Zhang XF; The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
  • Tang F; National Engineering Center for New Vaccine Research , Beijing, China.
  • Hou JW; The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
  • Liu ZM; National Engineering Center for New Vaccine Research , Beijing, China.
  • Han ZB; The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
  • Zhang H; National Engineering Center for New Vaccine Research , Beijing, China.
  • Du LF; The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
  • Shao S; National Engineering Center for New Vaccine Research , Beijing, China.
  • Su JG; The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
  • Liang Y; National Engineering Center for New Vaccine Research , Beijing, China.
  • Zhang J; The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
  • Li QM; National Engineering Center for New Vaccine Research , Beijing, China.
J Virol ; 97(10): e0093823, 2023 10 31.
Article em En | MEDLINE | ID: mdl-37792003
ABSTRACT
IMPORTANCE Human norovirus (HuNoV) is highly infectious and can result in severe illnesses in the elderly and children. So far, there is no effective antiviral drug to treat HuNoV infection, and thus, the development of HuNoV vaccines is urgent. However, NoV evolves rapidly, and currently, at least 10 genogroups with numerous genotypes have been found. The genetic diversity of NoV and the lack of cross-protection between different genotypes pose challenges to the development of broadly protective vaccines. In this study, guided by structural alignment between GI.1 and GII.4 HuNoV VP1 proteins, several chimeric-type virus-like particles (VLPs) were designed through surface-exposed loop grafting. Mouse immunization studies show that two of the designed chimeric VLPs induced cross-immunity against both GI.1 and GII.4 HuNoVs. To our knowledge, this is the first designed chimeric VLPs that can induce cross-immune activities across different genogroups of HuNoV, which provides valuable strategies for the development of cross-reactive HuNoV vaccines.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírion / Vacinas Virais / Infecções por Caliciviridae / Norovirus / Genótipo / Epitopos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírion / Vacinas Virais / Infecções por Caliciviridae / Norovirus / Genótipo / Epitopos Idioma: En Ano de publicação: 2023 Tipo de documento: Article